Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with CCRT in High-Risk NPC
NCT04223024Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2020
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Jan 2020; status: active, not recruiting.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04223024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223024.